Data from the PERSEUS trial support the FDA approval of the subcutaneous daratumumab-containing regimen in newly diagnosed multiple myeloma.
Approval Alert | Subcutaneous Daratumumab Combo in Newly Diagnosed Multiple Myeloma
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Pembrolizumab Formulation in Solid Tumors
2
Cevostamab Post-CAR T-Cell Therapy is Safe in Heavily Pretreated Multiple Myeloma
3
BPd Maintenance Safe, Yields Responses in High-Risk Multiple Myeloma
4
Cevostamab Combo Shows Enduring Responses in R/R Multiple Myeloma
5
